This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ACTG 175 was a randomized, double-blind phase II/III trial comparing monotherapy versus combination therapy with nucleoside analogs in HIV-infected persons with CD4 cells of 200-500/mm3. The registry identifies the trial as phase 2, with a primary purpose of treatment and an enrollment of 2100 participants.
| Feature | ACTG 175 |
|---|---|
| Study acronym | ACTG 175 |
| Registry identifier | NCT00000625 |
| Registry phase | Phase 2 |
| Study title | A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3 |
| Condition | HIV Infections |
| Design characteristic | Randomized, double-blind |
| Primary purpose | Treatment |
| Enrollment | 2100 |
| Status | Completed |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
2. Clinical Question
The clinical question described by the registry is whether monotherapy or combination therapy with nucleoside analogs should be compared in HIV-infected persons with CD4 cells of 200-500/mm3. The study was designed as a treatment trial with randomized allocation and double masking.
Population
HIV-infected persons with CD4 cells of 200-500/mm3.
Interventions
Zidovudine, zalcitabine, and didanosine are identified in the registry as study interventions.
Comparison
The study title specifies a comparison of monotherapy versus combination therapy with nucleoside analogs.
Primary question
How do randomized monotherapy and combination-therapy strategies compare in the specified HIV-infected population?
3. Trial Design
Monotherapy
- The study title specifies monotherapy as one of the treatment strategies.
- The registry identifies zidovudine, zalcitabine, and didanosine as study interventions.
- The available registry record does not provide treatment-specific dosing information in the record summarized here.
Combination therapy
- The study title specifies combination therapy as the comparator strategy.
- The combination strategy involved nucleoside analog therapy.
- The registry identifies zidovudine, zalcitabine, and didanosine as study interventions.
4. Endpoints
The registry record currently contains no registered primary endpoints for ACTG 175. Consequently, the record does not provide endpoint definitions, endpoint-specific assessment windows, event definitions, or prespecified primary-effect measures that can be reproduced in this analysis.
What a complete endpoint specification normally contains
A statistical endpoint should identify exactly what is measured, in whom it is measured, when it is assessed, and what constitutes an event or response. For a randomized treatment trial, this specification is important because the endpoint determines the appropriate estimand, analysis population, statistical model, handling of missing observations, and interpretation of the treatment contrast.
| Endpoint component | What should normally be specified | ACTG 175 registry record |
|---|---|---|
| Outcome | The clinical or laboratory quantity being measured | Not reported as a registered primary endpoint |
| Time frame | The prespecified assessment period or follow-up window | Not reported as a registered primary endpoint |
| Event definition | The criteria defining treatment success, failure, progression, or another event | Not reported as a registered primary endpoint |
| Analysis measure | For example, a mean difference, risk ratio, hazard ratio, or other effect measure | Not reported as a registered primary endpoint |
5. Statistical Methodology
Because the registry record contains no registered primary endpoints and no posted statistical analyses, the appropriate statistical framework has to be described at the level of the trial design rather than as a reconstruction of an endpoint-specific result.
Randomized comparison
Randomization is the central design feature for comparing monotherapy and combination therapy. If treatment assignment is randomized appropriately, the treatment groups are expected to be comparable in expectation with respect to measured and unmeasured baseline factors. This is what allows an observed difference in a prespecified outcome to be interpreted as a treatment-assignment contrast rather than simply an association between treatment choice and outcome.
Intention-to-treat principle
For a randomized comparative trial, the intention-to-treat principle generally analyzes participants according to their randomized treatment assignment. This preserves the comparison created by randomization and is particularly important when participants discontinue, switch therapy, or otherwise deviate from the assigned treatment strategy.
Endpoint-dependent analysis
The statistical model should be selected after defining the endpoint. A continuous outcome might be analyzed with a mean difference or regression model; a binary outcome might use a risk difference, risk ratio, odds ratio, or regression model; and a time-to-event endpoint would generally use Kaplan-Meier estimation and a suitable time-to-event comparison. The registry record does not identify which of these endpoint structures was prespecified for ACTG 175.
The exact statistical expression depends on the endpoint. The clinically meaningful quantity should be defined before choosing the corresponding statistical test or model.
Double masking
Double masking is a design feature intended to reduce the influence of treatment knowledge on participant behavior, clinical management, outcome assessment, and other processes that could affect observed outcomes. Its statistical value is strongest when the outcome can otherwise be influenced by expectations or differential assessment.
Multiplicity
Multiple interventions, multiple endpoints, multiple follow-up times, or multiple subgroup comparisons can create a multiplicity problem. When several statistical hypotheses are tested, the probability of obtaining at least one apparently positive result can exceed the nominal type I error rate unless the analysis plan specifies an appropriate error-control strategy.
The registry record summarized here does not provide a multiplicity strategy for ACTG 175. Therefore, no particular alpha allocation, hierarchical testing sequence, or adjustment procedure should be attributed to the trial on the basis of this record alone.
6. Statistical Methods Explained
Why does randomization matter statistically?
Randomization establishes the treatment comparison before outcomes are observed. In expectation, it balances prognostic characteristics between treatment groups, allowing differences in outcomes to be interpreted as consequences of assignment rather than simply differences between people who received different therapies.
Why does double masking matter?
Knowledge of treatment assignment can influence behavior and assessment. Double masking reduces opportunities for treatment expectations to systematically affect outcomes, adherence, co-interventions, or outcome measurement. The effect is particularly important for outcomes with subjective components.
Why must the endpoint be defined before choosing the statistical test?
A statistical method is a mathematical description of a particular type of outcome. A binary response, a continuous laboratory measurement, and time until an event require different probability models and different effect measures. Without a precise endpoint definition, it is not possible to identify one uniquely appropriate primary analysis.
Why is intention-to-treat important after randomization?
Analyzing participants according to their assigned group maintains the original randomized comparison. If participants who discontinue treatment are selectively removed from one group, the analysis can become more vulnerable to post-randomization differences that were not controlled by randomization.
What does a treatment effect estimate actually describe?
An effect estimate describes a contrast between treatment strategies on a specified outcome. For example, a risk difference compares probabilities, a mean difference compares average outcomes, and a hazard ratio compares modeled instantaneous event rates. The numerical meaning of an estimate therefore depends on the endpoint and statistical model.
Why is multiplicity important?
If many hypotheses are tested, at least one small p-value can occur by chance even when no treatment effect exists. A prespecified multiplicity strategy can control the overall probability of false-positive conclusions. Without knowing the testing hierarchy or error-control procedure, individual nominal p-values may be difficult to interpret as confirmatory evidence.
7. Planned Analysis
No formal statistical analyses are posted to ClinicalTrials.gov for this record. The registry also contains no registered primary endpoints in the record summarized here. As a result, the statistical analysis can be described at the level of the randomized treatment comparison, but no endpoint-specific estimate, confidence interval, or p-value is available from the registry.
How a trial of this design would normally be analyzed
| Outcome structure | Typical analysis | Key effect measure |
|---|---|---|
| Continuous outcome | Comparison of treatment-group means or an appropriate regression model | Mean difference or adjusted mean difference |
| Binary outcome | Comparison of event proportions or a binary regression model | Risk difference, risk ratio, or odds ratio |
| Time-to-event outcome | Kaplan-Meier estimation with a suitable treatment comparison and time-to-event model | Hazard ratio and/or survival probability |
| Repeated measurements | Longitudinal or mixed-effects modeling when repeated observations are part of the endpoint | Difference in trajectories or specified contrast |
The correct choice among these approaches depends on the actual prespecified endpoint, its measurement scale, its timing, and the analysis population. The registry record does not identify those details for a registered primary endpoint.
Confidence intervals
When a treatment effect is estimated, a confidence interval provides an interval of values compatible with the statistical model and observed information under the chosen confidence procedure. It conveys precision as well as the direction and magnitude of an estimate.
P-values
A p-value evaluates the compatibility of the observed data with a specified null hypothesis under the assumptions of the statistical test. It does not measure the size of a treatment effect, the probability that a treatment works, or the clinical importance of a finding.
8. Analysis Population and Missing Data
The randomized design makes the distinction between randomized participants, treated participants, and participants with complete outcome measurements statistically important. The registry record identifies the study as randomized and double-blind but does not specify analysis populations for particular endpoints.
Randomized population
The enrollment was 2100 participants. A primary efficacy analysis in a randomized trial would generally preserve treatment assignment rather than redefine groups based on treatment received.
Treated population
Safety or exposure analyses may use a treatment-exposed population, but the appropriate definition depends on the prespecified analysis plan.
Missing outcomes
Missing data can change the estimand and introduce bias if missingness is related to prognosis or treatment. The registry record does not specify a missing-data or imputation strategy.
Protocol deviations
Departures from assigned therapy can affect treatment-effect estimates. The registry record does not provide a protocol-deviation analysis framework.
For a continuous repeated outcome, complete-case analysis, mixed-effects models, multiple imputation, or other approaches may produce different estimands under different assumptions. For a time-to-event outcome, censoring rules are part of the endpoint definition itself. These choices therefore belong in the prespecified statistical analysis plan rather than being selected after observing results.
9. Non-Inferiority, Equivalence, and Superiority Logic
The registry title describes a comparison of monotherapy versus combination therapy. It does not identify a non-inferiority or equivalence objective, nor does it provide a non-inferiority margin.
No non-inferiority margin should therefore be attributed to ACTG 175 from the registry record summarized here.
10. Interim Analysis and Sequential Testing
The registry record does not provide an interim-analysis schedule, stopping boundaries, alpha-spending approach, or information fraction for ACTG 175.
In a trial with planned interim looks, repeatedly examining accumulating efficacy data can affect the overall type I error rate. Group-sequential methods address this by defining statistical boundaries or an alpha-spending function before the interim analyses. The appropriate boundary depends on the number and timing of looks and the prespecified error-control strategy.
Interim efficacy analysis
A prespecified interim analysis can allow early evidence of benefit or harm to influence trial continuation, but the decision rule must account for repeated testing.
Futility analysis
A futility rule can address whether continuing a study is unlikely to produce the intended evidence. Its interpretation depends on whether the rule is nonbinding or binding and on the prespecified operating characteristics.
Because these details are not reported in the registry record, no particular interim boundary or stopping rule is assigned to ACTG 175 here.
11. Multiplicity
ACTG 175 includes multiple named nucleoside analog interventions and a treatment comparison between monotherapy and combination therapy. If multiple treatment contrasts or multiple clinical outcomes were tested, the statistical interpretation would depend on the prespecified hierarchy of hypotheses.
| Multiplicity source | Why it matters | Registry information |
|---|---|---|
| Multiple treatment contrasts | Several comparisons can increase the chance of at least one nominally positive result | Specific testing hierarchy not reported |
| Multiple endpoints | Testing several outcomes can increase the familywise false-positive probability | Registered primary endpoints not reported |
| Subgroups | Repeated subgroup testing can produce apparently strong findings by chance | Prespecified subgroup strategy not reported |
| Repeated looks | Interim analyses can alter type I error if not accounted for | Interim-analysis strategy not reported |
A nominal p-value is therefore not automatically equivalent to confirmatory evidence when many hypotheses or repeated analyses are involved. The testing family and error-control strategy should be established prospectively.
12. Safety Analysis
The registry identifies zidovudine, zalcitabine, and didanosine as interventions, but it does not provide arm-specific serious adverse-event counts in the record summarized here.
| Safety component | Registry record |
|---|---|
| Serious adverse events by arm | Not reported in the available record |
| Arm-specific adverse-event counts | Not reported in the available record |
| Exposure-adjusted event rates | Not reported in the available record |
| Safety analysis population | Not specified in the available record |
Safety is statistically distinct from efficacy. The relevant unit may be a participant, an adverse-event episode, an exposure period, or a person-time interval, depending on the safety endpoint. For serious adverse events in particular, investigators may examine both the proportion of participants experiencing at least one event and the number and rate of events.
When treatment exposure differs between groups, an exposure-adjusted rate can provide information that a simple participant-level proportion does not. Conversely, participant-level incidence is often easier to interpret for whether an individual experienced at least one event. The endpoint definition determines which measure is appropriate.
13. Statistical Interpretation of a Randomized Treatment Comparison
Randomization allows the primary comparison to be framed as a contrast between treatment assignments. If the trial is conducted according to its randomized design, systematic differences in baseline prognosis should be reduced in expectation between groups.
Randomization does not make the observed groups numerically identical. Chance imbalance can occur, particularly for individual characteristics. It also does not eliminate missing data, treatment discontinuation, measurement error, or post-randomization events.
The meaning of a treatment comparison depends on what outcome is being contrasted. A statistically detectable difference in one biological or clinical measure does not automatically establish a difference in another outcome that was not measured or prespecified.
14. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The trial's randomized and double-blind design creates a framework for comparing monotherapy with combination therapy. The registry record does not contain a registered primary endpoint or posted statistical analysis from which a numerical treatment effect can be reported.
Clinical interpretation
The study addresses treatment strategies in HIV-infected persons with CD4 cells of 200-500/mm3. The clinical importance of any treatment difference depends on the specific outcomes measured, their timing, and the magnitude and precision of the observed effects.
15. Limitations
- Endpoint specification: the registry record contains no registered primary endpoints, so the primary outcome definition and time frame cannot be identified from the registry.
- No posted statistical analyses: ClinicalTrials.gov does not contain formal statistical analyses for this record from which endpoint-specific estimates, confidence intervals, or p-values can be reported.
- Analysis population: the registry record does not specify the population used for an efficacy or safety analysis.
- Missing data: no statistical strategy for missing observations or imputation is reported in the available registry record.
- Multiplicity: no detailed multiplicity-control strategy is reported, so the confirmatory status of potential multiple comparisons cannot be established from this record.
- Interim analyses: no interim-analysis schedule or stopping boundary is reported in the registry record.
- Treatment exposure: the registry identifies the interventions but does not provide dosing or detailed treatment-exposure information in the record summarized here.
- Safety: arm-specific serious adverse-event counts are not reported in the available registry record.
These limitations affect the statistical detail that can be assigned to the trial record. They do not change the underlying design description: ACTG 175 is registered as a randomized, double-blind treatment trial with an enrollment of 2100 participants.
16. Why This Trial Matters Statistically
ACTG 175 is a useful statistical teaching case because its design illustrates the importance of separating trial architecture from endpoint analysis. A randomized, double-blind design provides a strong framework for causal comparison, but the statistical conclusion ultimately depends on the outcome definition and prespecified analysis.
| Concept | How it appears in ACTG 175 |
|---|---|
| Randomization | The study title identifies a randomized comparison of monotherapy versus combination therapy. |
| Blinding | The registry identifies the masking as double. |
| Clinical population | HIV-infected persons with CD4 cells of 200-500/mm3. |
| Treatment comparison | Monotherapy versus combination therapy with nucleoside analogs. |
| Multiple interventions | Zidovudine, zalcitabine, and didanosine are identified as study interventions. |
| Analysis population | The registry record does not specify endpoint-specific analysis populations. |
| Endpoint definition | No registered primary endpoints are reported in the record. |
| Multiplicity | The registry record does not report a specific multiplicity-control strategy. |
| Interim analysis | The registry record does not report an interim-analysis schedule or boundary. |
| Missing data | The registry record does not report an imputation or missing-data strategy. |
| Safety analysis | Arm-specific serious adverse-event results are not reported in the available registry record. |
17. From Trial Design to Statistical Evidence
A useful way to understand ACTG 175 is to follow the logical chain from design to inference.
The first three components are documented in the registry. The fourth component is not represented by a registered primary endpoint in the record summarized here. That distinction is statistically important: without a prespecified outcome, there is no single primary effect measure that can be interpreted as the trial's principal statistical result.
For example, suppose a trial measures several outcomes. A treatment difference in a laboratory marker, a difference in clinical events, and a difference in time to an event are not interchangeable. Each has a different estimand, different assumptions, and potentially different clinical meaning.
This is why statistical analysis begins with the question "What exactly is the endpoint?" rather than "Which statistical test should be used?" The test follows the endpoint; it does not define it.
18. Randomization and Causal Interpretation
The randomized design provides the foundation for causal interpretation. If participants are assigned randomly to the treatment strategies, treatment assignment is not determined by the participant's prognosis or by the investigator's expectations. This allows the treatment groups to be compared as strategies rather than as naturally occurring groups.
Double masking adds another layer of protection against systematic differences after randomization. Participants and investigators who do not know treatment assignment may be less likely to change behavior, ancillary treatment, assessment, or reporting because of knowledge of the assigned intervention.
19. What Cannot Be Learned From a Treatment Label Alone
The registry identifies zidovudine, zalcitabine, and didanosine as interventions. That information establishes which study drugs were involved, but it does not by itself establish the size of any treatment effect.
A treatment comparison becomes statistically interpretable only when the outcome and analysis are specified. For example, knowing that two strategies contain different drugs does not tell us whether they differ in a continuous measurement, the probability of an event, the timing of an event, or another clinically relevant endpoint.
This distinction is especially important in historical clinical trials. A treatment name can be recognizable while the statistical meaning of a reported comparison still depends on the exact endpoint definition and analysis population.
20. Reading a Future Effect Estimate
If an endpoint-specific analysis is available from a sufficiently detailed statistical record, the effect estimate should be interpreted together with its confidence interval and the prespecified hypothesis.
| Reported quantity | What it tells the reader | What it does not establish by itself |
|---|---|---|
| Effect estimate | Magnitude and direction of the treatment contrast for a defined endpoint | Clinical importance without knowing the endpoint and context |
| 95% confidence interval | Statistical precision and uncertainty around the estimated effect | The range of effects experienced by individual patients |
| P-value | Compatibility of the data with a specified null hypothesis under the model | Probability that the treatment works or the size of the clinical benefit |
| Sample size | Amount of information enrolled in the trial | Whether a treatment effect is clinically important |
The same principle applies to safety outcomes. A difference in the number of participants experiencing at least one serious adverse event is not equivalent to a difference in the total number of adverse-event episodes or an exposure-adjusted event rate. The estimand must be identified before the numerical comparison is interpreted.
21. Sources
- ClinicalTrials.gov: NCT00000625 — ACTG 175.
Continue through Clinical Biostats
Explore statistical methods, clinical trial concepts, and analysis tools used to understand randomized clinical research.
22. Record Summary
ACTG 175 is registered as a randomized, double-blind phase 2 treatment trial involving 2100 HIV-infected persons with CD4 cells of 200-500/mm3. Its study title describes a comparison of monotherapy versus combination therapy with nucleoside analogs, and the registry identifies zidovudine, zalcitabine, and didanosine as interventions.
From a statistical perspective, the most important lesson is that trial design and statistical inference are connected but distinct. Randomization establishes the framework for a treatment comparison, double masking can reduce bias associated with knowledge of assignment, and the intervention structure defines the treatment strategies. The endpoint then determines the estimand and statistical model. Because the registry record contains no registered primary endpoints and no posted statistical analyses, the numerical efficacy or safety effect of the randomized comparison cannot be characterized from this registry record alone.